Statistik Asas
| CIK | 793160 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Igene Biotechnology, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| November 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement IGENE BIOTECHNOLOGY, INC. (Nam |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement IGENE BIOTECHNOLOGY, INC. (Nam |
|
| January 21, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):January 8, 2009 IGENE BIOTECHNOLOGY, INC. |
|
| January 21, 2009 |
LIMITED LIABILITY COMPANY AGREEMENT NATURXAN LLC INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, IS OMITTED AND IS NOTED WITH ****. |
|
| January 8, 2009 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 7) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin H. Neidell Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5836 (Name, Address and Telephone Nu |
|
| March 11, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 6) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| November 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2007 IGENE BIOTECHNOLOGY, INC. |
|
| November 6, 2007 |
SEPARATION AGREEMENT This Separation Agreement (this "Agreement") is made and entered into as of the 31st day of October, 2007 by and between Igene Biotechnology, Inc. |
|
| July 11, 2003 |
8-K/A 1 igene-8ka070903.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) May 6, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 0-15888 (Commissio |
|
| May 13, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) May 6, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 0-15888 (Commission File Number) 52-1230461 (IRS |
|
| May 13, 2003 |
Exhibit 1 Execution Copy JOINT VENTURE AGREEMENT BETWEEN TATE & LYLE FERMENTATION PRODUCTS LTD. |
|
| February 3, 2003 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 5) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and |
|
| September 17, 2002 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| September 17, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 5 [ ] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may contine. See Instruction 1(b). [ ] Form 3 Holdings Reported [X]Form 4 Transactions Reported OMB APPROVAL OMB NUMBER: 3235-0362 Expires: January 31, 2005 Estimated average burden hours pe |
|
| September 25, 2001 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| September 10, 2001 |
4 1 igene-4090601.htm 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 4 / / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) OMB APPROVAL OMB NUMBER: 3235-0287 Expires: December 31, 2001 Estimated average burden hours per response.........0.5 Filed pursuant |
|
| October 5, 2000 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone N |
|
| October 5, 2000 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 4 / / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) OMB APPROVAL OMB NUMBER: 3235-0287 Expires: December 31, 2001 Estimated average burden hours per response.........0.5 Filed pursuant to Section 16(a) of the |
|
| September 22, 2000 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 5 [ ] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may contine. See Instruction 1(b). [ ] Form 3 Holdings Reported [X]Form 4 Transactions Reported OMB APPROVAL OMB NUMBER: 3235-0362 Expires: December 31, 2001 Estimated average burden hours p |
|
| September 22, 2000 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 3) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Te |
